CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy

Muscle and Nerve

Volumn 44, Issue 2, 2011, Pages 174-178

  Spurney, Christopher F ^a   Carolina, Tesi Rocha ^a   Henricson, Erik ^a   Florence, Julaine ^b   Mayhew, Jill ^c   Gorni, Ksenija ^a   Pasquali, Livia ^a   Pestronk, Alan ^b   Martin, Gerard R ^a   Hu, Fengming ^a   Nie, Lei ^d   Connolly, Anne M ^b   Escolar, Diana M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Children's Hospital   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

Clinical trial; CoQ10; Duchenne muscular dystrophy; Muscle strength testing; Steroids

Indexed keywords

CORTICOSTEROID; MYOQUINON Q10; UBIDECARENONE; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DUCHENNE MUSCULAR DYSTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MUSCLE EXAMINATION; MUSCLE STRENGTH; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITATIVE MUSCLE TESTING; SCHOOL CHILD; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UBIQUINONE; VITAMINS;

EID: 79960497177     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22047     Document Type: Article

References (21)

1. Moxley RT III, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20.
2. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005;65:826-834.
3. Payne ET, Yasuda N, Bourgeois JM, Devries MC, Rodriguez MC, Yousuf J, et al. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 2006;33: 66-77.
4. Lonnrot K, Holm P, Lagerstedt A, Huhtala H, Alho H. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. Biochem Mol Biol Int 1998;44:727-737.
5. Okamoto T, Kubota N, Takahata K, Takahashi T, Goshima K, Kishi T. Protective effect of coenzyme Q10 on cultured skeletal muscle cell injury induced by continuous electric field stimulation. Biochem Biophys Res Commun 1995;216:1006-1012.
6. Rando TA, Crowley RS, Carlson EJ, Epstein CJ, Mohapatra PK. Overexpression of copper/zinc superoxide dismutase: a novel cause of murine muscular dystrophy. Ann Neurol 1998;44:381-386.
7. Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A, et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278:28220-28228.
8. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000;10:235-239.
9. Buyse GM, Goemans N, Henricson E, Jara A, van den Hauwe M, Leshner R, et al. CINRG pilot trial of oxatomide in steroid-naive Duchenne muscular dystrophy. Eur J Paediatr Neurol 2007;11: 337-340.
10. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005;58: 151-155.
11. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 1988;66:583-590.
12. Littarru GP, Mosca F, Fattorini D, Bompadre S, Battino M. Assay of coenzyme Q10 in plasma by a single dilution step. Methods Enzymol 2004;378:170-176.
13. Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, et al. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve 2001; 24:787-793.
14. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 2007;35:36-42.
15. Mendell JR, Province MA, Moxley RT III, Griggs RC, Brooke MH, Fenichel GM, et al. Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls. Arch Neurol 1987;44:808-811.
16. Verbeke G, Molenberghs G, Thijs H, Lesaffre E, Kenward MG. Sensitivity analysis for nonrandom dropout: a local influence approach. Biometrics 2001;57:7-14.
17. Verbeke G, Molenberghs G. The use of score tests for inference on variance components. Biometrics 2003;59:254-262.
18. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1995;1271:281-286.
19. Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci USA 1985;82:4513-4516.
20. Kaikkonen J, Tuomainen TP, Nyyssonen K, Salonen JT. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic Res 2002;36:389-397.
21. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 2005;26:768-771.